Exela Technologies - XELA Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exela Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XELA shares.
View XELA analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month price objectives for Exela Technologies' stock. Their XELA share price forecasts range from $11.00 to $40.00. On average, they predict the company's stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 1,646.6% from the stock's current price.
View analysts price targets for XELA or view top-rated stocks among Wall Street analysts.

Exela Technologies' stock was trading at $17.54 at the start of the year. Since then, XELA stock has decreased by 91.7% and is now trading at $1.46.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our XELA earnings forecast.

Exela Technologies, Inc. (NASDAQ:XELA) posted its quarterly earnings data on Friday, November, 5th. The company reported ($5.40) earnings per share for the quarter, missing the consensus estimate of ($3.40) by $2.00. The business earned $279.23 million during the quarter, compared to analysts' expectations of $310 million. During the same quarter in the previous year, the firm posted ($12.00) EPS.

Exela Technologies shares reverse split before market open on Tuesday, July 26th 2022. The 1-20 reverse split was announced on Tuesday, July 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

140 employees have rated Exela Technologies Chief Executive Officer Ron Cogburn on Glassdoor.com. Ron Cogburn has an approval rating of 46% among the company's employees. This puts Ron Cogburn in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exela Technologies investors own include Biocept (BIOC), Acasti Pharma (ACST), Avinger (AVGR), Bionano Genomics (BNGO), Heat Biologics (HTBX), T2 Biosystems (TTOO), Onconova Therapeutics (ONTX), Outlook Therapeutics (OTLK), AgEagle Aerial Systems (UAVS).

Exela Technologies trades on the NASDAQ under the ticker symbol "XELA."

Exela Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include B. Riley Financial Inc. (162.91%), Renaissance Technologies LLC (71.79%), Rafferty Asset Management LLC (11.18%), Equitec Proprietary Markets LLC (0.32%), Northern Trust Corp (3.28%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Apollo Management Holdings Gp,, Marc A Beilinson, Mark D Fairchild, Par Chadha, Shrikant Sortur and William L Transier.
View institutional ownership trends.

Shares of XELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XELA stock can currently be purchased for approximately $1.46.

Exela Technologies (NASDAQ:XELA) has a market capitalization of $32.27 million and generates $1.17 billion in revenue each year. The company earns $-142,390,000.00 in net income (profit) each year or ($16.42) on an earnings per share basis.

The company employs 17,000 workers across the globe.

Exela Technologies' mailing address is 2701 EAST GRAUWYLER ROAD, IRVING TX, 75061. The official website for the company is www.exelatech.com. The company can be reached via phone at 844-935-2832 or via email at ir@exelatech.com.